Drug
Bevacizumab clinical trials
Also written Avastin, SIBP-04, ABP 215 and Mvasi.
Includes 1 study of BEVZ92.
- studies test it
- 1,786
- open now
- 285
- in phase 3
- 268
- first study started
- 1998
Keep track of what changes. Save the Bevacizumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
1,774 studies that test it; most in 2006 (171); 1 more planned to start later
| Year | Studies |
|---|---|
| 1998 | 1 |
| 1999 | 1 |
| 2000 | 4 |
| 2001 | 13 |
| 2002 | 15 |
| 2003 | 19 |
| 2004 | 33 |
| 2005 | 90 |
| 2006 | 171 |
| 2007 | 144 |
| 2008 | 126 |
| 2009 | 124 |
| 2010 | 102 |
| 2011 | 63 |
| 2012 | 56 |
| 2013 | 63 |
| 2014 | 43 |
| 2015 | 35 |
| 2016 | 49 |
| 2017 | 56 |
| 2018 | 56 |
| 2019 | 45 |
| 2020 | 57 |
| 2021 | 65 |
| 2022 | 62 |
| 2023 | 66 |
| 2024 | 69 |
| 2025 | 81 |
| 2026 | 65 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 20
- Phase 1
- 390
- Phase 2
- 1,165
- Phase 3
- 268
- Phase 4
- 61
- No phase
- 74
What it is tested for
Each study’s main condition, where its own words name it.
- Glioblastoma
- 103
Who runs them
Industry 367 · Other 1,419
National Cancer Institute (NCI) (133) · Hoffmann-La Roche (86) · M.D. Anderson Cancer Center (64) · Genentech, Inc. (38) · Sun Yat-sen University (30) · SCRI Development Innovations, LLC (28) · Fudan University (27) · Memorial Sloan Kettering Cancer Center (22)
Often tested with
Tested in the same studies.
Paclitaxel (154) · Carboplatin (127) · Capecitabine (121) · Atezolizumab (99) · Oxaliplatin (99) · Irinotecan (78) · Fluorouracil (75) · Gemcitabine (72)
Studies
Open first, then newest update. How each study uses Bevacizumab is read from its arms, and is right about nine times in ten.
Testing it · 1,786
- Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP)Not yet recruitingPhase 2National Cancer Institute (NCI)NCT07756840Written as Bevacizumab
- First-line Treatment With Dual Immunotherapy Combined With Anti-angiogenesis for Unresectable Advanced Malignant Peritoneal MesotheliomaNot yet recruitingPhase 2Fudan UniversityNCT07893340Written as Bevacizumab
- Longitudinal Study of Retinal Function in Eyes Treated for Diabetic Macular Edema With Anti-VEGF AgentsRecruitingPhase 4Jaeb Center for Health ResearchNCT07567833Written as Anti-Vascular Endothelial Growth Factor
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial CancerRecruitingPhase 3National Cancer Institute (NCI)NCT07198074Written as Bevacizumab
- Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerRecruitingPhase 3National Cancer Institute (NCI)NCT04181060Written as Bevacizumab
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06843447Written as Bevacizumab
- PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver CancerRecruitingPhase 2Samsung Medical CenterNCT07884877Written as Immune checkpoint inhibitor-based therapy
- SBRT Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for Hepatocellular CarcinomaNot yet recruitingPhase 2Peking University Cancer Hospital & InstituteNCT07882056Written as Bevacizumab
- Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal CancerRecruitingPhase 2Gilead SciencesNCT07527858Written as Bevacizumab
- A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal CancerRecruitingPhase 2AbbVieNCT06820463Written as Bevacizumab
- The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)RecruitingPhase 2Inova Health Care ServicesNCT06789757Written as Bevacizumab
- Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP TrialRecruitingPhase 2City of Hope Medical CenterNCT07288034Written as Bevacizumab
- BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or OligometastasesRecruitingPhase 2Shandong Cancer Hospital and InstituteNCT07062055Written as Anti-VEGF
- ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal CancerRecruitingEarly Phase 1M.D. Anderson Cancer CenterNCT07318389Written as Bevacizumab
- A Prospective, Single-center, Phase II Study of Neoadjuvant Serplulimab Plus XELOX and Bevacizumab in Locally Advanced Rectal CancerNot yet recruitingNot applicableTang-Du HospitalNCT07854964Written as Bevacizumab
- Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain MetastasesRecruitingPhase 1/2Melanoma and Skin Cancer Trials LimitedNCT06163820Written as Bevacizumab
- First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian CancerRecruitingPhase 1/2Accent TherapeuticsNCT06799065Written as ATX-295 and bevacizumab (or biosimilar)
- A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian CancerRecruitingPhase 2AbbVieNCT07059845Written as Bevacizumab
- A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)RecruitingPhase 1Hoffmann-La RocheNCT04929223Written as Bevacizumab
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT03424005Written as Bevacizumab
See all 1,786 studies that test Bevacizumab →
Given in every arm · 493 — Bevacizumab is usual care beside what is tested
- A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular CarcinomaRecruitingPhase 1/2Tvardi Therapeutics, IncorporatedNCT05440708Written as Bevacizumab
- A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid TumorsRecruitingPhase 1Vividion Therapeutics, Inc.NCT06004245Written as Bevacizumab
- A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07776691Written as Bevacizumab
- A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.RecruitingPhase 2AbbVieNCT06890338Written as Bevacizumab
- Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance TherapyRecruitingPhase 2National Cancer Institute (NCI)NCT07504588Written as Bevacizumab
- The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical TrialsRecruitingPhase 4PfizerNCT05203172Written as Bevacizumab
- A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]RecruitingPhase 2Nanjing Leads Biolabs Co.,LtdNCT07111546Written as Bevacizumab Injection
- FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal CancerRecruitingPhase 2Oncolytics BiotechNCT07446322Written as Bevacizumab
- A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal CancerRecruitingPhase 3AbbVieNCT07525206Written as Bevacizumab
- FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)Not yet recruitingPhase 2Sun Yat-sen UniversityNCT07621497Written as Bevacizumab
- A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07743164Written as Bevacizumab
- A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal CarcinomaRecruitingPhase 1/2Nanjing Leads Biolabs Co.,LtdNCT07791758Written as Bevacizumab injection
- Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian CancerRecruitingPhase 3AstraZenecaNCT07816666Written as Bevacizumab
- Study of Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant Ovarian, Fallopian Tube, and Peritoneal CancerNot yet recruitingPhase 1Rebecca ArendNCT07772882Written as Bevacizumab
- ONO-4538 Phase II Rollover Study (ONO-4538-98)RecruitingPhase 2Ono Pharmaceutical Co., Ltd.NCT04566380Written as bevacizumab
- Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400RecruitingPhase 1AbbVieNCT06084481Written as Bevacizumab
- Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS TumorsRecruitingPhase 2Medical University of ViennaNCT01356290Written as Bevacizumab
- Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular CarcinomaRecruitingPhase 3AstraZenecaNCT06921785Written as Bevacizumab
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06824467Written as Bevacizumab
- A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian CancerRecruitingPhase 1AbbVieNCT07278336Written as Bevacizumab
Showing 20 of 493.
As the comparator · 100 — what is tested is compared with Bevacizumab
- A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal CancerRecruitingPhase 2/3Bristol-Myers SquibbNCT07221357Written as Bevacizumab
- A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)RecruitingPhase 3GlaxoSmithKlineNCT07286266Written as Bevacizumab
- Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)RecruitingPhase 3GenmabNCT07775287Written as Bevacizumab
- Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal CancerRecruitingPhase 3PfizerNCT07222800Written as Bevacizumab
- 5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal CancerRecruitingPhase 2The Methodist Hospital Research InstituteNCT06887218Written as Bevacizumab
- A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06997497Written as Bevacizumab
- Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal CancerRecruitingPhase 3Summit TherapeuticsNCT07228832Written as Drug: Bevacizumab Injection
- XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS MutationEnrolling by invitationPhase 1/2Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.NCT06936527Written as Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI
- A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received ChemotherapyRecruitingPhase 3Janssen Research & Development, LLCNCT06750094Written as Bevacizumab
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP TrialRecruitingPhase 3ECOG-ACRIN Cancer Research GroupNCT05863195Written as Bevacizumab
- JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver CancerNot yet recruitingPhase 3Shanghai Junshi Bioscience Co., Ltd.NCT07823348Written as Bevacizumab
- ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer"RecruitingPhase 2Gruppo Oncologico Italia MeridionaleNCT07381764Written as Bevacizumab
- Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C MutationRecruitingPhase 3AmgenNCT06252649Written as Bevacizumab-awwb
- A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian CancerRecruitingPhase 2CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07714668Written as paclitaxel, carboplatin, bevacizumab
- Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High StatusNot yet recruitingPhase 4Gruppo Oncologico del Nord-OvestNCT07094893Written as Bevacizumab
- A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal CancerRecruitingPhase 3Seagen, a wholly owned subsidiary of PfizerNCT05253651Written as bevacizumab
- A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal CancerRecruitingPhase 1/2BioNTech SENCT07079631Written as Bevacizumab
- PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical CancerRecruitingPhase 2/3N.N. Alexandrov National Cancer CentreNCT07472153Written as Chemotherapy and bevacizumab (CT-BEV)
- Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver MetastasesNot yet recruitingPhase 2UNICANCERNCT07359456Written as Bevacizumab
- A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent GlioblastomaRecruitingPhase 2BioNTech SENCT07297212Written as Bevacizumab
Showing 20 of 100.
Codes
What other systems call Bevacizumab · ClinicalTrials.gg INT006505
- MeSH (NLM) D000068258BevacizumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 2S9ZZM9Q9VBEVACIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 253337Confirmed FDA, Wikidata
- Wikidata Q413299bevacizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C2039BevacizumabOne source FDA
- DrugBank DB00112One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000068258 | Bevacizumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 2S9ZZM9Q9V | BEVACIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 253337 | — | Confirmed FDA, Wikidata |
| Wikidata | Q413299 | bevacizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C2039 | Bevacizumab | One source FDA |
| DrugBank | DB00112 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.